| |
| |
|
| Insider
Information: |
Protopapas Anna |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
152,388 |
|
|
Indirect Shares
|
318,355 |
|
|
| Direct
Value |
$522,871 |
|
|
|
Indirect Value
|
$987,522 |
|
|
| Total
Shares |
470,743 |
|
|
| Total
Value |
$1,510,393 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -206.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Millennium Pharmaceuticals Inc |
MLNM |
Senior Vice President |
2008-05-14 |
0 |
2008-05-01 |
5,848 |
Premium* |
|
|
Ariad Pharmaceuticals Inc |
ARIA |
Director |
2016-02-01 |
23,902 |
2016-02-01 |
0 |
Premium* |
|
|
Bioverativ Inc. |
BIVV |
Director |
2018-03-08 |
0 |
2017-04-17 |
0 |
Premium* |
|
|
Mersana Therapeutics, Inc. |
MRSN |
Director |
2024-01-16 |
125,153 |
2024-01-16 |
312,507 |
Premium* |
|
|
Dicerna Pharmaceuticals Inc |
DRNA |
Director |
2021-06-03 |
3,333 |
2021-06-03 |
0 |
Premium* |
|
|
Nuvalent, Inc. |
NUVL |
Director |
2023-12-18 |
0 |
2023-12-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2024-01-16 |
4 |
AS |
$2.71 |
$79,671 |
D/D |
(29,399) |
125,153 |
0 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2024-01-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,958 |
154,552 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,750 |
115,594 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2024-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
98,844 |
0 |
- |
|
| NUVL |
Nuvalent, Inc. |
Director |
– • – |
2023-12-18 |
4 |
S |
$75.67 |
$378,350 |
D/D |
(5,000) |
0 |
0 |
- |
|
| NUVL |
Nuvalent, Inc. |
Director |
– • – |
2023-12-18 |
4 |
OE |
$9.36 |
$46,800 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2023-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,643 |
67,594 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2023-01-17 |
4 |
S |
$5.74 |
$99,566 |
D/D |
(17,346) |
48,733 |
0 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2023-01-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,958 |
66,079 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,750 |
27,121 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2022-05-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
240,244 |
240,244 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2022-05-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
240,244 |
10,371 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2022-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,958 |
322,878 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2021-07-19 |
4 |
S |
$12.02 |
$263,250 |
D/D |
(21,901) |
282,978 |
0 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2021-07-16 |
4 |
S |
$12.47 |
$249,936 |
D/D |
(20,043) |
304,879 |
0 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2021-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
324,922 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • – |
2021-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
3,333 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2021-01-15 |
4 |
D |
$21.09 |
$109,626 |
D/D |
(5,198) |
224,922 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President & CEO |
• • – |
2021-01-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,709 |
230,120 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Director |
• • – |
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,056) |
0 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President and CEO |
• • – |
2017-12-20 |
4 |
OE |
$1.53 |
$15,938 |
D/D |
10,417 |
130,719 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President and CEO |
• • – |
2017-07-03 |
4 |
A |
$0.00 |
$0 |
I/I |
72,263 |
192,565 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
President and CEOOfficer |
• • – |
2017-06-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
120,302 |
|
- |
|
| BIVV |
Bioverativ Inc. |
Director |
• • – |
2017-04-17 |
4 |
A |
$56.83 |
$60,012 |
D/D |
1,056 |
1,056 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,902 |
23,902 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
